Compare PAYP & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYP | TWST |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 9.2B |
| IPO Year | 2025 | 2018 |
| Metric | PAYP | TWST |
|---|---|---|
| Price | $14.78 | $120.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | $24.06 | ★ $168.25 |
| AVG Volume (30 Days) | 508.2K | ★ 2.4M |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $24.65 | $21.17 |
| Revenue Next Year | $18.06 | $20.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $12.07 | $23.30 |
| 52 Week High | $24.89 | $219.71 |
| Indicator | PAYP | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 38.85 |
| Support Level | $14.37 | $79.90 |
| Resistance Level | $16.41 | $155.44 |
| Average True Range (ATR) | 0.65 | 15.43 |
| MACD | 0.06 | -3.39 |
| Stochastic Oscillator | 35.48 | 4.11 |
PayPay is a financial technology company jointly owned by Softbank and LY. It was founded in 2018, following the success of Alipay and WeChat Pay in China, and was the pioneering code payment app in Japan. Over the past seven years, it has amassed more than 70 million users and is the market leader in code payments.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.